'''Assertio Therapeutics, Inc.''' (formally Depomed, Inc.) is an American Specialty [[Specialty pharmaceuticals|specialty pharmaceuticalPharmaceutical]] company which mainly markets products for treatment in [[neurology]], [[pain]] and diseases of the [[central nervous system]].<ref name=":0">{{cite web|url = https://www.google.com/finance?cid=660571|title = Depomed Inc: NASDAQ:DEPO quotes & news|accessdate = Jan 29, 2014|website = Google Finance}}</ref> Depomed was founded in 1995 and is headquartered in [[Newark, California]].<ref>{{Cite web|title = DEPO Profile {{!}} Depomed, Inc. Stock|url = https://finance.yahoo.com/q/pr?s=DEPO+Profile|website = Yahoo! Finance|accessdate = Jan 2, 2016}}</ref> The company is a publicly traded company on [[NASDAQ]] under the symbol "DEPOASRT", with several products approved by the United States [[Food and Drug Administration]] (FDA). On August 15th 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc.<ref>https://www.cnbc.com/2018/08/15/globe-newswire-depomed-inc-announces-corporate-name-change-to-assertio-therapeutics-inc.html</ref>
